F-star, Takeda Agree to Antibody Development Collaboration

Published on: 

Partnership to focus on developing immunotherapies for patients with cancer.

F-star Therapeutics, a biopharmaceutical company, has announced a strategic partnership with Takeda. As per the deal, the organizations will jointly research and develop novel Fcab ™ domains against undisclosed immuno-oncology targets for cancer patients, with Takeda receiving exclusive royalty-bearing license to research, develop, and commercialize antibodies incorporating Fcab domains. F-star will retain the rights on other domains.


“We are delighted to expand our relationship with Takeda who shares our vision of developing pioneering multi-specific immunotherapies so more people with cancer can live longer with improved lives,” said Neil Brewis, PhD, chief scientific officer, F-star Therapeutics. “This strategic collaboration leverages the capabilities of both companies by combining F-star’s clinically validated Fcab™ and mAb² ™ platforms with Takeda’s unique understanding of the immune system and its ability to progress drugs to the clinic.”

Reference: F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies. GlobeNewswire. July 5, 2023. Accessed July 6, 2023. https://www.globenewswire.com/news-release/2023/07/05/2699446/0/en/F-star-an-invoX-Company-Announces-Strategic-Collaboration-and-Licence-Agreement-with-Takeda-to-Discover-and-Develop-Next-Generation-Multi-Specific-Antibodies.html